The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib

Leukemia. 2013 Jun;27(6):1416-8. doi: 10.1038/leu.2013.14. Epub 2013 Jan 16.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzothiazoles / therapeutic use*
  • Drug Resistance, Neoplasm / genetics
  • Female
  • Humans
  • Indoles / therapeutic use*
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / genetics*
  • Middle Aged
  • Mutation*
  • Phenylurea Compounds / therapeutic use*
  • Pyrroles / therapeutic use*
  • Staurosporine / analogs & derivatives*
  • Staurosporine / therapeutic use
  • Sunitinib
  • fms-Like Tyrosine Kinase 3 / genetics*
  • fms-Like Tyrosine Kinase 3 / physiology

Substances

  • Antineoplastic Agents
  • Benzothiazoles
  • Indoles
  • Phenylurea Compounds
  • Pyrroles
  • quizartinib
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3
  • Staurosporine
  • midostaurin
  • Sunitinib